Find → Understand → Decide
Bcl-XL Proteolysis Targeting Chimera DT2216
Discovery priority: LOW · POSSIBLE / INVESTIGATE
Discovery priority ≠ investment recommendation. These are observation labels, not verified canonical products. Buyer qualification: UNKNOWN.
Why investigate?
Why stranded (event context): safety failure
Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established
Company/trial failed before biology? UNKNOWN
Biology implicated: UNCLEAR · Failure context: DRUG/BIOLOGY
MODEL INFERENCE · LOW confidence. Explicit asset-linked program event or documented experimental trial arm, stop scope, dated recency and biological cautions; no publication count or buyer-gate input.
Current control: UNKNOWN · Restart: UNKNOWN · Development reuse: UNKNOWN
Next diligence: Confirm present program status and exact product identity, then trace scoped rights/data/CMC and review arm-level human outcomes.
Existing buyer gates
Human Signal: UNKNOWN
Cheap Truth: UNKNOWN
Clean Rights: UNKNOWN
Market Pull: UNKNOWN
No event or publication count supplies missing gate evidence. Existing reviewed opportunities remain in their original records.
Evidence timeline
2026-08-24 · trial:NCT06620302
Registry update date, not proven program-stop date
SOURCE TEXT · Exact source
Unacceptable Toxicity
Trial reason is not attributed to every intervention; comparator/combination context needs review.
Interpretation: safety failure · AUTO_INFERRED · MEDIUM
Provenance and retrieval scope
{
"hash": "bc9a7f015a55b9960d44486e04c1a3624d360162b57077242f3ac11f7e9775d6",
"metadata": {
"complete": false,
"content_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
"failed": false,
"last_checked": 1790026985.182528,
"last_success": 1790026985.182528,
"live_verified": true,
"scope": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
},
"path": "protocolSection.armsInterventionsModule.interventions",
"raw_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
"raw_path": "research/obz7_sources/2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed.json",
"request_params": {
"countTotal": "true",
"format": "json",
"pageSize": 100,
"query.term": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
"sort": "LastUpdatePostDate:desc"
},
"request_url": "https://clinicaltrials.gov/api/v2/studies",
"type": "clinicaltrials",
"url": "https://clinicaltrials.gov/study/NCT06620302"
}Freshness is claim-specific
Fetching an old filing today does not establish current ownership or program status.
pipeline · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
sec · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
rights · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
contact · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
patent_assignment · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
clinicaltrials · STALE · AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:05.182528+00:00
Registry observations (1)
NCT06620302 · SUSPENDED · PHASE1, PHASE2 · Childhood Fibrolamellar Carcinoma; Recurrent Childhood Fibrolamellar Carcinoma; Recurrent Childhood Malignant Solid Neoplasm; Recurrent Fibrolamellar Carcinoma; Recurrent Malignant Solid Neoplasm; Refractory Childhood Fibrolamellar Carcinoma; Refractory Childhood Malignant Solid Neoplasm; Refractory Fibrolamellar Carcinoma; Refractory Malignant Solid Neoplasm · Trial sponsor Children's Oncology Group
Reported aliases: Antiapoptotic Protein Targeted Degrader DT2216; APTaD DT2216; Bcl-XL Degrader DT2216; Bcl-XL PROTAC DT2216; BCL-XL-specific PROTAC DT2216; DT 2216; DT-2216; DT2216; PROTAC Bcl-XL Deagrader DT2216; PROTAC DT2216; Proteolysis-targeting Chimera Protein Degrader DT2216. Identity, treatment role and exposure require review.